Fluticasone

is prescribed to treat:

• Asthma and allergic rhinitis • Various related conditions in the respiratory category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Fluticasone (Flovent, Flonase, Arnuity) is a corticosteroid available as an inhaler for asthma and COPD, as a nasal spray for allergic rhinitis, and as a topical preparation for inflammatory skin disease. The delivery route changes almost everything about how it behaves, and the three formulations should be thought of as different treatments that happen to share a molecule.

Mechanism of Action

Fluticasone binds intracellular glucocorticoid receptors, and the receptor complex moves to the nucleus where it alters gene transcription — suppressing pro-inflammatory cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory mediators.

In the airway this reduces eosinophilic inflammation, mucosal edema, mucus production, and bronchial hyperresponsiveness. Because asthma is fundamentally an inflammatory disease, this addresses the cause rather than the consequence — the essential difference from a bronchodilator such as albuterol, which relieves symptoms while leaving the underlying inflammation untouched.

The property that makes inhaled and intranasal delivery viable is high first-pass metabolism. Fluticasone that is swallowed rather than deposited in the airway is extensively metabolised by the liver before reaching the systemic circulation, so systemic exposure is a small fraction of what an equivalent oral dose would produce. This is why an inhaled corticosteroid does not carry the adrenal suppression, bone loss, and glucose effects that govern prednisone use — at usual doses.

At high doses over long periods, systemic effects do appear, and they are not zero. Fluticasone propionate in particular is a CYP3A4 substrate, and strong inhibitors — ritonavir and some antifungals — can raise systemic levels enough to cause Cushing's syndrome and adrenal suppression from an inhaled drug, a genuinely surprising interaction worth knowing about.

Clinical Use

For asthma, inhaled corticosteroids are the foundation of controller therapy at every level of persistent disease. Current guidance has moved away from short-acting beta agonist monotherapy even in mild asthma, favouring an inhaled corticosteroid taken regularly or combined with a fast-onset bronchodilator as needed, because this reduces severe exacerbations. A patient whose only asthma medication is a rescue inhaler is on an outdated regimen.

Onset is gradual — days to weeks for full effect — which patients must understand, because an inhaled corticosteroid does nothing for an acute attack and feels like it is doing nothing at all in the first days. Adherence to a preventive inhaler that produces no immediate sensation is genuinely difficult, and it is the main practical challenge in asthma care.

In COPD, inhaled corticosteroids have a narrower role than they once did. They are added for frequent exacerbations, particularly with eosinophilia, but they increase pneumonia risk in this population and are not appropriate for every patient with COPD.

The nasal spray is first-line for allergic rhinitis and is more effective than oral antihistamines for nasal congestion specifically — the symptom antihistamines address least well. The Florida allergies article covers the year-round exposure pattern here, and our pulmonary team manages difficult asthma.

Technique and Rinsing

Two practical points determine whether an inhaled corticosteroid works and whether it causes side effects.

Rinsing the mouth and spitting after every inhaled dose prevents oral candidiasis and dysphonia, the two most common local adverse effects. Drug deposited in the oropharynx rather than the airway causes both. This instruction is routinely given and routinely forgotten, and a patient with recurrent thrush on an inhaled steroid is almost always a patient who is not rinsing.

Inhaler technique degrades over time even after good initial teaching, and a substantial proportion of patients use their device incorrectly enough to lose much of the delivered dose. A spacer improves delivery considerably with a metered-dose inhaler and is under-used in adults. Checking technique at least annually is among the highest-value and least glamorous interventions in respiratory care — often more useful than escalating therapy. The American Lung Association provides technique guidance.

For the nasal spray, aiming away from the nasal septum reduces irritation and epistaxis, which is the most common reason patients abandon it.

Monitoring and Follow-Up

Asthma control should be assessed objectively rather than by impression: symptom frequency, rescue inhaler use, night waking, activity limitation, and exacerbations requiring oral steroids. Rescue inhaler use more than twice a week indicates inadequate control regardless of what a patient reports, since people normalise their own symptom burden.

Spirometry confirms diagnosis and tracks obstruction. At high doses or with long-term use, growth should be monitored in children — inhaled corticosteroids produce a small reduction in growth velocity, which is real but modest and must be weighed against the substantial harm of undertreated asthma.

Oral candidiasis should be looked for at review. Bone density and cataract or glaucoma risk warrant consideration with prolonged high-dose therapy, particularly alongside courses of oral steroids. The MedlinePlus fluticasone entry covers prescribing detail.

Stepping down once control is sustained is part of good asthma management and is done less often than it should be — patients are frequently left on high doses indefinitely after a period of poor control has long resolved.

Special Populations

In children, inhaled corticosteroids are the controller of choice and the growth effect is outweighed by the benefit; spacers with masks improve delivery in young children substantially.

In pregnancy, asthma should be treated actively, since uncontrolled asthma poses a clearer risk to the fetus than the medication does. Budesonide has the largest accumulated pregnancy dataset among inhaled corticosteroids, but fluticasone is used and continuing an effective controller is preferred to switching.

In older adults with COPD, pneumonia risk is the main consideration and argues for reserving inhaled corticosteroids for those with a clear exacerbation or eosinophilic phenotype. Patients on ritonavir or strong CYP3A4 inhibitors need an alternative or close monitoring.

When to Contact Your Doctor

Seek emergency care for severe breathing difficulty — an inhaled corticosteroid has no role in an acute attack, and a rescue inhaler that is not working, or relief lasting less than four hours, is an emergency.

Report increasing rescue inhaler use, night waking with symptoms, or reduced exercise tolerance, which indicate deteriorating control. Report white patches in the mouth or a persistently hoarse voice, which usually mean rinsing is being missed. Report persistent nosebleeds with the nasal spray.

Ask to have your inhaler technique checked at least once a year. If your asthma has been well controlled for several months, ask whether the dose can be stepped down.

To review your asthma or allergy control, check technique, or discuss stepping treatment up or down, contact us or schedule a visit.